Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation
Atrial FibrillationA multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial scar mapping in addition to pulmonary vein isolation (PVI) when compared to PVI alone in patients with persistent atrial fibrillation (AF).
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 and up
Critères de participation
Inclusion Criteria:
1. Age ≥18 years ;
2. Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for AF
3. At least one episode of AF that is sustained beyond 3 months in duration ; documented on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within 36 months of enrollment in the study;
4. Modified DR-FLASH score \>=4
4. Subjects must be able to provide informed consent.
Exclusion Criteria:
1. History of previous catheter ablation for AF or left atrial flutter;
2. History of previous surgical ablation for AF;
3. Known intracardiac thrombus;
4. Contraindication to systemic oral anticoagulation therapy;
5. Reversible causes of AF;
6. Hypertrophic cardiomyopathy;
7. Severe valvular disease (mitral/aortic stenosis or regurgitation);
8. Subjects that are pregnant or breastfeeding;
9. Comorbid condition with life expectancy \< 1 year
Lieu de l'étude
Southlake Regional Health Centre
Southlake Regional Health CentreNewmarket, Ontario
Canada
Contactez l'équipe d'étude
Atul Verma, MD
Vancouver General Hospital
Vancouver General HospitalVancouver, British Columbia
Canada
Contactez l'équipe d'étude
Jason Andrade, MD
Centre Hospitalier de l'Universite de Montreal (CHUM)
Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, Quebec
Canada
Contactez l'équipe d'étude
Jean-Marc Raymond, MD
Institute Universitaire de Cardiologie et Pneumologie du Quebec (IUCPQ)
Institute Universitaire de Cardiologie et Pneumologie du Quebec (IUCPQ)Quebec City, Quebec
Canada
Contactez l'équipe d'étude
Isabelle Nault, MD
Libin Cardiovascular Institute
Libin Cardiovascular InstituteCalgary, Alberta
Canada
Contactez l'équipe d'étude
George Veenhuyzen, MD
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contactez l'équipe d'étude
Allan Skanes, MD
Rouge Valley Regional Heart Centre
Rouge Valley Regional Heart CentreToronto, Ontario
Canada
Contactez l'équipe d'étude
Derek Yung, MD
Montreal Heart Institute
Montreal Heart InstituteMontreal, Quebec
Canada
Contactez l'équipe d'étude
Laurent Macle, MD
QEII Health Sciences Centre, Nova Scotia Health Authority
QEII Health Sciences Centre, Nova Scotia Health AuthorityHalifax, Nova Scotia
Canada
Contactez l'équipe d'étude
John Sapp, MD
University of Ottawa Heart Institute
University of Ottawa Heart InstituteOttawa, Ontario
Canada
Contactez l'équipe d'étude
Sacre-Coeur Hospital
Sacre-Coeur HospitalMontreal, Quebec
Canada
Contactez l'équipe d'étude
Mario Sturmer, MD
CIUSSS de L'Estrie-CHUS-Hopital Fleurimont
CIUSSS de L'Estrie-CHUS-Hopital FleurimontSherbrooke, Quebec
Canada
Contactez l'équipe d'étude
Charles Dussault, MD
Hamilton General Hospital
Hamilton General HospitalHamilton, Ontario
Canada
Contactez l'équipe d'étude
Jorge Wong, MD
St. Michael's Hospital
St. Michael's HospitalToronto, Ontario
Canada
Contactez l'équipe d'étude
Paul Angaran, MD
McGill University Health Centre
McGill University Health CentreMontreal, Quebec
Canada
Contactez l'équipe d'étude
Vidal Essebag, MD
- Étude parrainée par
- Ottawa Heart Institute Research Corporation
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT03347227